We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Quality Assurance Unit has not ensured sufficient mitigation of the risk of introduction of visible protein aggregates intravenously to patients receiving the drug product.